Risperidone Augmentation in Patients With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, risperidone, prolactin, clozapine
Eligibility Criteria
Inclusion Criteria: Clinical DSM-IV diagnosis of schizophrenia (any subtype) based on chart review and patient interview by research psychiatrist Ages 18-65 Stable residual psychiatric symptoms defined as PANSS score greater than 60 On clozapine monotherapy with plasma level of at least 200 ng/mL (unless the patient refuses a dose adjustment or does not tolerate a higher dose) On clozapine for at least 6 months and at a stable dose for at least 8 weeks Competent to provide informed consent. If the subject has a guardian, assent must be given by the subject and consent must be given by the guardian. Exclusion Criteria: Chart diagnosis of dementia or another neurodegenerative disorder, mental retardation, or a pervasive developmental disorder Suicidal ideation Substance use disorder (excluding nicotine use) in the past 3 months Any unstable medical illness Pregnancy or breast-feeding Investigational agent in past 30 days History of adverse reaction to risperidone
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
risperdone
placebo